» Articles » PMID: 19462483

Evaluation of the Transport, in Vitro Metabolism and Pharmacokinetics of Salvinorin A, a Potent Hallucinogen

Overview
Specialty Pharmacology
Date 2009 May 23
PMID 19462483
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Salvinorin A is an unregulated potent hallucinogen isolated from the leaves of Salvia divinorum. It is the only known non-nitrogenous kappa-opioid selective agonist, and rivals synthetic lysergic acid diethylamide (LSD) in potency. The objective of this study was to characterize the in vitro transport, in vitro metabolism, and pharmacokinetic properties of Salvinorin A. The transport characteristics of Salvinorin A were assessed using MDCK-MDR1 cell monolayers. The P-glycoprotein (P-gp) affinity status was assessed by the P-gp ATPase assay. In vitro metabolism studies were performed with various specific human CYP450 isoforms and UGT2B7 to assess the metabolic characteristics of Salvinorin A. Cohorts (n = 3) of male Sprague Dawley rats were used to evaluate the pharmacokinetics and brain distribution of Salvinorin A (10 mg/kg, intraperitoneal (i.p.) over a 240-min period. A validated UV-HPLC and LC/MS/MS method was used to quantify the hallucinogen concentrations obtained from the in vitro and in vivo studies, respectively. Salvinorin A displayed a high secretory transport in the MDCK-MDR1 cells (4.07 +/- 1.34 x 10(-)5 cm/s). Salvinorin A also stimulated the P-gp ATPase activity in a concentration (5 and 10 microM)-dependent manner, suggesting that it may be a substrate of (P-gp). A significant decrease in Salvinorin A concentration ranging from 14.7 +/- 0.80% to 31.1 +/- 1.20% was observed after incubation with CYP2D6, CYP1A1, CYP2C18, and CYP2E1, respectively. A significant decrease was also observed after incubation with UGT2B7. These results suggest that Salvinorin A maybe a substrate of UGT2B7, CYP2D6, CYP1A1, CYP2E1, and CYP2C18. The in vivo pharmacokinetic study showed a relatively fast elimination with a half-life (t1/2) of 75 min and a clearance (Cl/F) of 26 L/h/kg. The distribution was extensive (Vd of 47.1 L/kg); however, the brain to plasma ratio was 0.050. Accordingly, the brain half-life was relatively short, 36 min. Salvinorin A is rapidly eliminated after i.p. dosing, in accordance with its fast onset and short duration of action. Further, it appears to be a substrate for various oxidative enzymes and multi-drug resistant protein, P-gp.

Citing Articles

Emerging Psychotropic Drug for the Treatment of Trigeminal Pain: Salvinorin A.

Quinonez-Bastidas G, Grijalva-Contreras L, Patino-Camacho S, Navarrete A Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770461 PMC: 11728561. DOI: 10.3390/ph17121619.


Harnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy.

Halman A, Conyers R, Moore C, Khatri D, Sarris J, Perkins D Clin Pharmacol Ther. 2024; 117(1):106-115.

PMID: 39345195 PMC: 11652822. DOI: 10.1002/cpt.3459.


A Route to Potent, Selective, and Biased Salvinorin Chemical Space.

Hill S, Dao N, Dang V, Stahl E, Bohn L, Shenvi R ACS Cent Sci. 2023; 9(8):1567-1574.

PMID: 37637743 PMC: 10450872. DOI: 10.1021/acscentsci.3c00616.


Solving an Old Puzzle: Elucidation and Evaluation of the Binding Mode of Salvinorin A at the Kappa Opioid Receptor.

Puls K, Wolber G Molecules. 2023; 28(2).

PMID: 36677775 PMC: 9861206. DOI: 10.3390/molecules28020718.


Pharmacokinetics and Pharmacodynamics of Salvinorin A and : Clinical and Forensic Aspects.

Machado Brito-da-Costa A, Dias-da-Silva D, Gomes N, Dinis-Oliveira R, Madureira-Carvalho A Pharmaceuticals (Basel). 2021; 14(2).

PMID: 33546518 PMC: 7913753. DOI: 10.3390/ph14020116.


References
1.
Butelman E, Harris T, Kreek M . The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl). 2003; 172(2):220-4. DOI: 10.1007/s00213-003-1638-0. View

2.
Wang Q, Rager J, Weinstein K, Kardos P, Dobson G, Li J . Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm. 2004; 288(2):349-59. DOI: 10.1016/j.ijpharm.2004.10.007. View

3.
Sumnall H, Wagstaff G, Cole J . Self-reported psychopathology in polydrug users. J Psychopharmacol. 2004; 18(1):75-82. DOI: 10.1177/0269881104040239. View

4.
King C, Green M, Rios G, Coffman B, Owens I, Bishop W . The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch Biochem Biophys. 1996; 332(1):92-100. DOI: 10.1006/abbi.1996.0320. View

5.
Pindel E, Kedishvili N, Abraham T, Brzezinski M, Zhang J, Dean R . Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J Biol Chem. 1997; 272(23):14769-75. DOI: 10.1074/jbc.272.23.14769. View